Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
|ClinicalTrials.gov Identifier: NCT00899327|
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : May 12, 2009
Last Update Posted : July 8, 2009
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients at risk of developing myelodysplastic syndrome may help doctors learn more about changes that occur in DNA and identify biomarkers related to disorders of the blood and bone marrow.
PURPOSE: This research study is looking at biomarkers in patients at risk of developing myelodysplastic syndrome or other disorders and in healthy participants.
|Condition or disease||Intervention/treatment|
|Leukemia Myelodysplastic Syndromes||Genetic: DNA methylation analysis Genetic: RNA analysis Genetic: cytogenetic analysis Genetic: gene expression analysis Genetic: mutation analysis Genetic: polymerase chain reaction Genetic: protein expression analysis Other: laboratory biomarker analysis|
- To identify novel biomarkers of disease that would help in the initial diagnosis of myelodysplastic syndromes (MDS).
- To understand the genesis of anemia in cancers.
- To identify novel biomarkers of disease that predict progression of MDS to acute myeloid leukemia.
OUTLINE: Blood and bone marrow samples are collected. Hemopoietic stem cells (HSC) and progenitor cells are isolated from samples for analysis. Some of these HSC and progenitor cells are used for functional assays. From the rest of the cells, DNA, RNA, and protein is extracted for molecular analyses, including gene mutation analysis, gene methylation assays, chromatin immunoprecipitation, microarray, and real-time polymerase chain reaction.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Molecular and Functional Characterisation of Bone Marrow Function in Normal Subjects, Myelodysplastic Syndromes (MDS) and Secondary Disorders of Heamatopoiesis|
|Study Start Date :||January 2007|
|Estimated Primary Completion Date :||December 2011|
- Identification of novel biomarkers of disease
- Identification of novel biomarkers of disease progression from myelodysplastic syndromes to acute myeloid leukemia
- Comprehension of genesis of anemia in cancer
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899327
|Oxford Radcliffe Hospital||Recruiting|
|Oxford, England, United Kingdom, 0X3 9DU|
|Contact: Contact Person 44-1865-222-309 email@example.com|
|Principal Investigator:||Vyas Paresh, MD||Oxford University Hospitals NHS Trust|